A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
Status:
Recruiting
Trial end date:
2022-10-21
Target enrollment:
Participant gender:
Summary
This is a 2-part, open-label, interventional study conducted in approximately 42 subjects
with AML harboring an IDH2 mutation.
The overall study is a 3-arm investigation of the PK effects of enasidenib at steady state on
the probe compounds. (Part 1), followed by treatment continuation up to 28 months (Part 2).
Each arm utilizes different probe compounds; enrolls a separate cohort of approximately 14
subjects; and consists of 2 parts - investigation of the PK effects of enasidenib on the
respective probe compound(s) (Part 1), followed by an enasidenib treatment extension (Part
2).